Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
This combination regimen consists of goserelin, a gonadotropin-releasing hormone (GnRH) agonist, and the HER2-targeted monoclonal antibodies pertuzumab and trastuzumab. It is being evaluated by Peking Union Medical College in a Phase 2 umbrella trial (NCT05933408) for the treatment of salivary gland carcinoma, specifically for patients whose tumors are both androgen receptor (AR)-positive and human epidermal growth factor receptor 2 (HER2)-positive. Goserelin induces medical castration to suppress androgen-driven tumor growth, while trastuzumab and pertuzumab provide dual blockade of the HER2 receptor to inhibit dimerization and downstream oncogenic signaling. In the clinical trial context, this triplet is often administered alongside an AR antagonist to achieve comprehensive blockade of the AR and HER2 pathways.
- Other names
- goserelin + pertuzumab + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on goserelin + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + pertuzumab + trastuzumab.